parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.06 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in melanocytes	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	3 Parkinson's papers of 115	0.82
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 4355

SLC1A4 in astrocytes, braak-0.08 (p 0.840) → -0.37 (p 0.323)receipt 4363
SLC1A4 in dopamine neurons, braak+0.15 (p 0.699) → -0.46 (p 0.209)receipt 4364

receipt 4364: SLC1A4 in dopamine neurons, braak

power: full sample -0.10 (p 0.683, n 18), 95% CI -0.54 to +0.38. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.11 (p 0.671, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.11 (p 0.671, n 18). could be the mix.
skeptic: leave-one-out range -0.23 to +0.01, sign flips 2; without severely affected donors -0.10 (p 0.683, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SLC1A4 in dopamine neurons.

case closed: nothing better to follow up.

receipt 4363: SLC1A4 in astrocytes, braak

power: full sample -0.26 (p 0.306, n 18), 95% CI -0.65 to +0.24. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.17 (p 0.504, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.14 (p 0.585, n 18). could be the mix.
skeptic: leave-one-out range -0.38 to -0.15, sign flips 0; without severely affected donors -0.26 (p 0.306, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SLC1A4 in astrocytes.

case closed: nothing better to follow up.

loading the receipts